Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2020 Aug 29;15(1):24–27. doi: 10.1016/j.pcd.2020.08.015

Diabetes and COVID-19: A pooled analysis related to disease severity and mortality

Seshadri Reddy Varikasuvu a,⁎, Naveen Dutt b, Balachandar Thangappazham c, Saurabh Varshney d
PMCID: PMC7456278  PMID: 32891525

Highlights

  • •

    COVID-19 pandemic in the diabetes community has become a worldwide concern.

  • •

    The association between diabetes and COVID-19 progression was studied by pooled analysis.

  • •

    COVID-19 patients with diabetes have a significantly higher risk of disease severity (OR = 2.20, 95% CI = 1.69–2.86, p  < 0.00001).

  • •

    COVID-19 patients with diabetes have a significantly higher mortality outcomes risk (OR = 2.52, 95% CI = 1.93–3.30, p  < 0.00001).

Keywords: COVID-19, Comorbidities, Diabetes

Abstract

Globally, COVID-19 has become a major concern for the diabetic community. We conducted a pooled analysis and constructed a forest plot for the association between diabetes and COVID-19 progression in 47 studies. A random effects meta-analysis (Mantel–Haenszel method) was conducted to estimate the outcomes effect size as odds ratios (OR) and 95% confidence intervals (CI) using Review Manager Software version 5.3. COVID-19 patients with diabetes have a significantly higher risk of disease severity (OR = 2.20, 95% CI = 1.69–2.86, p < 0.00001) and associated mortality outcomes (OR = 2.52, 95% CI = 1.93–3.30, p =  < 0.00001).

1. Introduction

Ever since the outbreak of coronavirus disease 2019 (COVID-19) due to a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the number of infected cases and associated mortalities due to COVID-19 are growing. Studies have linked fatal outcomes in COVID-19 to the associated comorbidities. Evidence reported in the Journal of Diabetes and Centers for Disease Control and Prevention (CDC) showed diabetes as the most important comorbidity associated with a 50% higher risk of fatal outcomes in COVID-19 cases with diabetes than their non-diabetic counterparts [1], [2], [3]. Considering the global concern for COVID-19 pandemic in the diabetes community, we aim to evaluate the risk of disease severity and mortality in association with diabetes in COVID-19 patients.

2. Methods

This meta-analysis was planned as a part of our PROSPERO registered protocol (CRD42020186661), and relevant studies were identified through searching PubMed, Cochrane, medRxiv and other databases. Studies reporting diabetic proportions in subgroups of COVID-19 patients (Severe vs. Non-severe & Mortal vs. Survival) were included. Other study types and reports with no data on diabetic numbers were excluded.

2.1. Outcomes

The proportions of COVID-19 patients with diabetes in severe/mortal & non-severe/survival groups were used to estimate the risk of disease progression associated with diabetes. Further, a separate outcome analysis was conducted to study the relationship of diabetes with disease severity (Severe vs. Non-severe) and mortality (Survival vs. Non-survival) in COVID-19

2.2. Statistical analysis

A random effects meta-analysis (Mantel-Haenszel method) was conducted to estimate the outcomes effect size as odds ratios (OR) and 95% confidence intervals (CI) using Review Manager Software version 5.3. The stability and publication bias were tested by a one-study leave-out sensitivity analysis and funnel plot asymmetry, respectively. Heterogeneity was assessed using the I 2 statistic. A p-value of < 0.05 was considered to be statistically significant. More information on literature search and results are presented in the Supplementary Material.

3. Results

3.1. Subjects and pooled results

In this meta-analysis, a total of 47 relevant studies were included for the pooled outcome analysis [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50]. All the studies confirmed diagnosis using the real-time reverse transcription polymerase chain reaction test. Overall, the diabetic proportions were 1009/3773 and 1360/9495 in severe/mortal and non-severe/survival groups of COVID-19 cases, respectively. The pooled outcome for the risk of disease progression indicated a significant impact of diabetes in COVID-19 cases (OR = 2.32, 95% CI = 1.90–2.83, Z  = 8.30, p  < 0.00001, I 2  = 55%, p  < 0.0001) (Fig. 1 ). The symmetrical funnel plot shown in Fig. 2 suggests no publication bias and sensitivity analysis indicated that the stability of overall result is not influenced by leaving-out any particular study. More information on search results, study characteristics and quality assessment are presented in the Supplementary Table 1.

Fig. 1.

Fig. 1

Open in a new tab

Forest plot relating diabetes to disease severity and survival in COVID-19 patients from 47 studies.

Fig. 2.

Fig. 2

Open in a new tab

The funnel plot of studies included in the analysis.

3.2. Diabetes and risk of severity and mortality

The diabetic proportions were 750/2894 and 931/6203 in severe and non-severe groups of COVID-19 cases, respectively. And, the respective diabetic proportions were 259/879 and 429/3292 in mortal and survival groups of COVID-19. As shown in Fig. 1, the subgroup analysis showed that diabetes related significantly with COVID-19 disease severity (OR = 2.20, 95% CI = 1.69–2.86, Z  = 5.82, p  < 0.00001, I 2  = 58%, p  < 0.0001) and mortality (OR = 2.52, 95% CI = 1.93–3.30, Z  = 6.79, p  < 0.00001, I 2  = 31%, p  = 0.08) as well. Though no significant heterogeneity was observed for the association of diabetes with mortality outcomes, the overall results should be viewed with caution to the heterogenous coexisting comorbidities across the included studies.

4. Discussion

Our results clearly indicate risk of disease progression and mortality is significantly high in COVID-19 patients with diabetes than in those without diabetes. It has been reported that individuals with impaired glucose tolerance or diabetes to have 50–60% higher risk of pulmonary infection [2], [3]. Recent evidence suggests an increased risk of severe Adult Respiratory Distress Syndrome and multi-organ failure complications in diabetic patients. Globally, during the COVID-19 pandemic, diabetic cases consists of up to 50% COVID-19 cases [3].

As an important comorbid metabolic disorder, diabetes characterised by hyperglycemia has been reported to downregulate immune response and increased inflammation. It has also been proposed that coronavirus through angiotensin-converting enzyme 2 (ACE2) receptors may result in cell damage and disease progression [2], [3]. The available evidence shows that the presence of diabetes in COVID-19 makes them more prone for disease progression and fatal outcomes. Our results are in support of the scientific/clinical opinion that COVID-19 patients with diabetes should be given much attention considering the associated higher risk of mortality in COVID-19 patients with diabetes. The recommendations and special considerations proposed for managing diabetic patients with COVID-19 are available elsewhere [1], [2], [3].

To summarise, this pooled analysis with a large sample size of 13,268 COVID-19 patients indicates significant association between diabetes and COVID-19 progression. COVID-19 patients with diabetes have a significantly higher risk of disease severity (OR = 2.20, 95% CI = 1.69–2.86, p  < 0.00001) and associated mortality outcomes (OR = 2.52, 95% CI = 1.93–3.30, p  < 0.00001). Considering the rapidly growing number of research reports, future meta-analyses with systematic review of literature are warranted to establish the independent associations of individual comorbidities for the risk of COVID-19 disease progression and mortality.

Conflict of interest

The authors declare no conflict of interest.

Acknowledgement

Dr. S.R. Varikasuvu thanks Bhairavi Sisters (Sahasra & Agneya) for the time I could not give you during this work.

Footnotes

Appendix A

Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.pcd.2020.08.015.

Appendix A. Supplementary data

The following are the supplementary data to this article:

mmc1.docx (37.6KB, docx)

References

  • 1.Beran D., Aebischer Perone S., Castellsague Perolini M. Beyond the virus: ensuring continuity of care for people with diabetes during COVID-19. Prim. Care Diabetes. 2020 doi: 10.1016/j.pcd.2020.05.014. S1751-9918(20)30199-6 [published online ahead of print, 2020 May 30] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Wang W., Lu J., Gu W., Zhang Y., Liu J., Ning G. Care for diabetes with COVID-19: advice from China. J. Diabetes. 2020;12(5):417–419. doi: 10.1111/1753-0407.13036. [DOI] [PubMed] [Google Scholar]
  • 3.Bornstein S.R., Rubino F., Khunti K. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546–550. doi: 10.1016/S2213-8587(20)30152-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Auld Sara C., Caridi-Scheible M., Blum James M., Robichaux C., Kraft C., Jacob Jesse T. ICU and ventilator mortality among critically ill adults with coronavirus disease. Crit Care Med 2019. 2020:1–6. doi: 10.1097/CCM.0000000000004457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Guang C., Di W., Wei G., Yong C., Da H., Hongwu W. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 2020;130(5):2620–2629. doi: 10.1172/JCI137244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Ruchong C., Ling S., Mei J., Zhaowei Y., Nan J., Wanyi F. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China. J. Allergy Clin. Immunol. 2020 doi: 10.1016/j.jaci.2020.05.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Jun D., Xiaohui W., Jing C., Hong C., Linfu B., Qianfang H. Correlation between the variables collected at admission and progression to severe cases during hospitalization among COVID-19 patients in Chongqing. J. Med. Virol. 2020 doi: 10.1002/jmv.26082. jmv.26082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Yong G., Tuantuan L., Mingfeng H., Xiuyong L., Dong W., Yuanhong X. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J. Med. Virol. 2020;(February) doi: 10.1002/jmv.6082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Guan W., Ni Z., Hu Yu, Liang W., Ou C., He J. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382(18):1708–1720. doi: 10.1056/NEJMoa2002032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Ting G., Qinxue S., Wei G., Wenlong H., Jinhua L., Yi Z. Clinical characteristics of elderly patients with COVID-19 in Hunan province, china: a multicenter, retrospective study. Gerontology. 2020:1–9. doi: 10.1159/000508734. [DOI] [PubMed] [Google Scholar]
  • 11.Chaolin H., Yeming W., Xingwang L., Lili R., Jianping Z., Yi H. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Fengjun L., Qi Z., Chao H., Chunzi S., Lin W., Nannan S. CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients. Theranostics. 2020;10(12):5613–5622. doi: 10.7150/thno.45985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Jing L., Sumeng L., Jia L., Boyun L., Xiaobei W., Hua W. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020:55. doi: 10.1016/j.ebiom.2020.102763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Tao L., Jieying Z., Yuhui Y., Hong M., Zhenyu L., Jiaoyue Z. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol. Med. 2020 doi: 10.15252/emmm.202012421. emmm.202012421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Yanli L., Wenwu S., Liangkai C., Yujun W., Lijuan Z., Li Y. Clinical characteristics and progression of 2019 novel coronavirus-infected patients concurrent acute respiratory distress syndrome. MedRxiv. 2020 doi: 10.1101/2020.02.17.20024166. 2020.02.17.20024166. [DOI] [Google Scholar]
  • 16.Hongzhou L., Jingwen A., Yinzhong S., Yingchuan L.Y., Tao L., Xian Z. A descriptive study of the impact of diseases control and prevention on the epidemics dynamics and clinical features of SARS-CoV-2 outbreak in Shanghai, lessons learned for metropolis epidemics prevention. MedRxiv. 2020 doi: 10.1101/2020.02.19.20025031. 2020.02.19.20025031. [DOI] [Google Scholar]
  • 17.Zhihua L., Shaohua C., Juan L., Jingtao H., Lina F., Binghong Z. Clinical characteristics and co-infections of 354 hospitalized patients with COVID-19 in Wuhan, China: a retrospective cohort study. Microbes Infect. 2020 doi: 10.1016/j.micinf.2020.05.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Ling M., Huijuan J., Mengdie W., Yu H., Shengcai C., Quanwei H. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020:1–8. doi: 10.1001/jamaneurol.2020.1127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Pingzheng, M., Yuanyuan, X., Yu, X., Liping, D., Qiu, Z. Clinical characteristics of refractory COVID-19 pneumonia, n.d.
  • 20.Peng Y.D., Meng K., Guan H.Q., Leng L., Zhu R.R., Wang B.Y. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48(December 2019):E004. doi: 10.3760/cma.j.cn112148-20200220-00105. [DOI] [PubMed] [Google Scholar]
  • 21.Petrilli Christopher M., Jones Simon A., Jie Y., Harish R., Luke O., Yelena C. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966. doi: 10.1136/bmj.m1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Giulia R., Vincenza D.S., Francesco I., Massimiliano B., Martina G., Domenica D.C. Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients. Andrology. 2020 doi: 10.1111/andr.12821. andr.12821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Weifeng S., Junwu D., Yali R., Ming T., Wei L., Jianwu H. The value of clinical parameters in predicting the severity of COVID-19. J. Med. Virol. 2020 doi: 10.1002/jmv.26031. jmv.26031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Yu S., Xia Y., Hong Z., Hao W., Ruihong Z., Jifang S. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit. Care. 2020;24(1):2–5. doi: 10.1186/s13054-020-2833-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Smadja David M., Guerin Coralie L., Richard C., Nader Y., Jeremy B., Nicolas G. Characteristics and prognostic factors of disease severity in patients with COVID-19: the Beijing experience. Angiogenesis. 2020 doi: 10.1007/s10456-020-9730-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Ying S., Yanli D., Lifeng W., Huan X., Baosen L., Christopher C. Characteristics and prognostic factors of disease severity in patients with COVID-19: the Beijing experience. J. Autoimmun. 2020:102473. doi: 10.1016/j.jaut.2020.102473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Jianbo T., Xianglin Y., Jun X., Qiang Z., Chunguang Y., Bo L. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;0(0) doi: 10.1016/S1470-2045(20)30309-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Suxin W., Yi X., Wei F., Yu Z., Boqun L., Yanjun H. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J. Med. Virol. 2020;(March):1–10. doi: 10.1002/jmv.25783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Chang-Zheng W., Shun-Lin H., Lin W., Min L., Huan-Tian L. Early risk factors of the exacerbation of Coronavirus disease 2019 pneumonia. J. Med. Virol. 2020 doi: 10.1002/jmv.26071. jmv.26071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Dawei W., Bo H., Chang H., Fangfang Z., Xing L., Jing Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA – J. Am. Med. Assoc. 2020;323(11):1061–1069. doi: 10.1001/jama.2020.1585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Zhongliang W., Bohan Y., Qianwen L., Lu W., Ruiguang Z. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin. Infect. Dis. 2020:1–9. doi: 10.1093/cid/ciaa272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Chaomin W., Xiaoyan C., Yanping C., Jia’an X., Xing Z., Sha X. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 2020:1–10. doi: 10.1001/jamainternmed.2020.0994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Qiuxiang Y., Ling X., Wei Z., Lin Z., HuaJun W., Jie J. Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019. J. Clin. Pharm. Ther. 2020 doi: 10.1111/jcpt.13170. jcpt.13170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Qingchun Y., Peng W., Xingguang W., Guoqiang Q., Mei M., Xiwen T. Retrospective study of risk factors for severe SARS-Cov-2 infections in hospitalized adult patients. Polish Arch. Intern. Med. 2020 doi: 10.20452/pamw.15312. [DOI] [PubMed] [Google Scholar]
  • 35.Jin Jin Z., Xiang D., Yi Yuan C., Ya Dong Y., Yi Bin Y., You Qin Y. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy Eur. J. Allergy Clin. Immunol. 2020;(February):1–12. doi: 10.1111/all.14238. [DOI] [PubMed] [Google Scholar]
  • 36.Yang Z., Haichao L., Jian Z., Yedi C., Xue Z., Nan Y. The clinical characteristics and outcomes of diabetes mellitus and secondary hyperglycaemia patients with coronavirus disease 2019: a single-center, retrospective, observational study in Wuhan. Diabetes Obes. Metab. 2020 doi: 10.1111/dom.14086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Yi Z., Li-Jun S., Mi X., Jian P., Yun-Tao Z., Xue-Ling F. Clinical characteristics of 34 COVID-19 patients admitted to intensive care unit in Hangzhou, China. J. Zhejiang Univ. Sci. B. 2020;21(5):378–387. doi: 10.1631/jzus.B200074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Yongli Z., Hong X., Ming Y., Yilan Z., Hong C., Ru L. Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu. J. Clin. Virol. 2020;127:104366. doi: 10.1016/j.jcv.2020.104366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Tao C., Wu D.I., Huilong C., Weiming Y., Danlei Y., Guang C. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020:368. doi: 10.1136/bmj.m1091. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Marta C., María J.P.-S., Dolores R.-P., Laura L.-M., Milagro M.M., Judith V. COVID-19 in elderly kidney transplant recipients. Am. J. Transplant. 2020 doi: 10.1111/ajt.16096. ajt.16096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Weina G., Mingyue L., Yalan D., Haifeng Z., Zili Z., Chunxia T. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab. Res. Rev. 2020;(March):1–9. doi: 10.1002/dmrr.3319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Xiaomin, L., Wei, Z., Xiaojie, Y., China Tangxi G., Lu, Y., Jun, X., et al. Prognostic value of C-reactive protein in patients with COVID-19, n.d. DOI:10.1093/cid/ciaa641/5843450.
  • 43.Simin M., Xiaoquan L., Zhe C., Shenghao T., Kai Q. Clinical characteristics of critically ill patients co-infected with SARS-CoV-2 and the influenza virus in Wuhan, China. Int. J. Infect. Dis. 2020 doi: 10.1016/j.ijid.2020.05.068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Kun W., Peiyuan Z., Yuwei L., Meng Z., Xiaofang Z., Songpu X. Clinical and laboratory predictors of in-hospital mortality in 305 patients with COVID-19: a cohort study in Wuhan, China. SSRN Electron. J. 2020 doi: 10.2139/ssrn.3546115. [DOI] [Google Scholar]
  • 45.Yongli Y., Yan Y., Fen W., Huihui R., Shujun Z., Xiaoli S. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Diabetes Res. Care. 2020;8(1):1–9. doi: 10.1136/bmjdrc-2020-001343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Xiaobo Y., Yuan Y., Jiqian X., Huaqing S., Jia’an X., Hong L. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2020;8(5):475–481. doi: 10.1016/S2213-2600(20)30079-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Mingli Y., Wen Y., Zhaowu T., Weijun T., Yi H. Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China. PLoS One. 2020;15(3):1–10. doi: 10.1371/journal.pone.0230548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Alberto Z., Luigi B., Mara S.A., Giacomo M., Evgeny F., Sergio C. Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy. Crit Care Resusc. 2020:1–12. doi: 10.1016/S1441-2772(23)00387-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Jinping Z., Peng L., Morong W., Jie W., Jie C., Wenling Y. The clinical data from 19 critically ill patients with coronavirus disease 2019: a single-centered, retrospective, observational study. J. Public Heal. 2020:2–5. doi: 10.1007/s10389-020-01291-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Fei Z., Ting Y., Ronghui D., Guohui F., Ying L., Zhibo L. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

mmc1.docx (37.6KB, docx)

Articles from Primary Care Diabetes are provided here courtesy of Elsevier

RESOURCES